BMY - Bristol-Myers Squibb Co.
SNP 500


Weak GrowthEarnings/Profit is Negative


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 15.42%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -11.89%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.47
Debt Ratio is 0.66
Current Debt to Net Income Ratio is 3.28
Total Debt to Total Assets Ratio is 0.45
Cash Flow is STRONG
Cash from Operations Growth is 20.4%
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Bristol-Myers Squibb Co. (BMY) -
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Giovanni Caforio
Employees - 30,250

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.